An experimental skin cancer drug from Genentech Inc. and Curis Inc. showed positive results in a mid-stage clinical trial.
South San Francisco-based Genentech, part of Swiss drug maker Roche Group, did not disclose details of its 104-patient, Phase II study of vismodegib, or GDC-0449, in advanced basal cell carcinoma. The study, however, met its primary goal of overall response rate in shrinking tumors by a pre-defined percentage, the company said.
No comments:
Post a Comment